logo
Swiss Shock - Can Switzerland Reverse The 39% Tariff?

Swiss Shock - Can Switzerland Reverse The 39% Tariff?

Forbes7 hours ago
The imposition of a 39% tariff on Swiss exports to the US has been greeted with shock, despair and much ire in Switzerland – the main newspaper NZZ greeting the move as 'absurd'. Considerable offense was taken by the fact that the announcement came on the Swiss National holiday (August 1st). Equally, local business leaders and economists have been perplexed by the fact that the tariffs have been calculated on the back of a trade deficit that was skewed by the export of gold – the deficit is now a surplus.
Equally, many of the goods that Switzerland exports to the US, do not have competitors there (Swiss chocolate, watches and more importantly specialized industrial goods which are used by the likes of Boeing). Neither is the Swiss franc a weak currency.
There is also a feeling in Switzerland that its role on the international stage, and facilitator of American diplomacy (the Swiss embassy in Tehran has traditionally acted 'for' the US), has gone un-noticed.
Swiss politics is normally a very staid affair but this episode has led to infighting across the spectrum, and considerable blame has been focused on the President of the government Council, Karin Keller-Sutter. As a result, the Swiss negotiating team that will return to Washington this week will have representation from the conservative SVP, and more officials from the trade and finance divisions.
The Swiss case highlights the flaws in the methodology of the White House approach. While its economy is extremely resilient, the Swiss will not be able to suffer a 39% tariff lightly. Our sense is that the counterargument will centre around a re-framing of the trade relationship between the two countries, a re-evaluation of how Swiss industry in particular helps US firms, and an undertaking for Swiss industry to invest in the US.
The hope here is that Switzerland ends up with an EU style deal, of tariffs of 15%, and a somewhat empty promise to invest 'billions' into the US.
From a diplomatic point of view, given that the Swiss had traditionally been so helpful to US interests, this is an own-goal by the White House. At the time of writing, there is no indication at all as to whether this episode pushes Switzerland closer to the EU (in terms of trade – there is no question of Switzerland joining the EU).
For its part, the EU is still trying to get the White House to agree the wording of deal reached in Scotland – there is ongoing lobbying from the spirits industry in Europe, not to mention the auto manufacturers. The deal is not yet watertight and needs to be implemented by individual members. There is still uncertainty over the threats to place specific tariffs on semiconductors and pharmaceuticals firms based in Europe next week (Ireland in particular) and the USD 600bn that is supposed to be invested by European firms in the US. If sector specific tariffs are severe the backlash to the deal could grow and there is rising chance that it could fall apart.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Is Calling for Intel CEO Lip-Bu Tan to Resign. What Does That Mean for INTC Stock?
Trump Is Calling for Intel CEO Lip-Bu Tan to Resign. What Does That Mean for INTC Stock?

Yahoo

time24 minutes ago

  • Yahoo

Trump Is Calling for Intel CEO Lip-Bu Tan to Resign. What Does That Mean for INTC Stock?

Intel (INTC) shares are down more than 3% today after the U.S. president demanded that Lip-Bu Tan – the company's chief executive – 'resign immediately.' According to President Donald Trump, Tan is 'highly CONFLICTED' and there is 'no other solution to this problem.' More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Including today's decline, Intel stock is down nearly 30% versus its year-to-date high set in February. Why Is Trump's Post Negative for Intel Stock? Investors are choosing caution on INTC shares this morning as the president's social media post highlights political and reputational risks tied to the company's leadership. An administrative demand for Tan to resign introduces meaningful uncertainty around corporate governance and strategic continuity. Labeling him as 'highly CONFLICTED' possibly due to ties with China-based businesses raises fears of national security scrutiny, especially amid heightened U.S.-China trade tensions. Earlier this week, Sen. Tom Cotton, R-Ark wrote a letter to the chairman of the Intel board of directors questioning these alleged ties, including to Cadence Design Systems (CDNS), which just plead guilty to violating U.S. export controls. All in all, Trump's comment signals potential regulatory pressure and leadership instability ahead, risks that may further hurt Intel stock in the second half of 2025. INTC Shares Continue to Face Challenges Trump's remarks add to a string of challenges facing Intel shares that made Seaport Global analysts maintained their 'Sell' rating on the semiconductor company last week. According to the investment firm, INTC stock isn't worth owning despite an attractive valuation since it may continue to lose market share to competitors like Advanced Micro Devices (AMD), particularly in high-performance computing and AI-driven workloads. Moreover, a recently announced NEX spinoff adds complexity to INTC's corporate structure. It's more of a defensive move than a growth catalyst, Seaport told clients in its latest research note. Wall Street Sees Significant Upside in Intel Despite several headwinds threatening Intel's stock price recovery, Wall Street hasn't really thrown in the towel on INTC shares yet. While the consensus rating on the semiconductor stock remains at 'Hold' only, the mean target of about $23 indicates potential upside of roughly 17% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Yahoo

time24 minutes ago

  • Yahoo

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Eli Lilly reported growth of 172% and 68% for weight loss drug Zepbound and type 2 diabetes (T2D) treatment Mounjaro, respectively, in Q2 2025, though ceded early advantage to Novo Nordisk in the oral glucagon-like receptor agonist (GLP-1RA) arena. Eli Lilly's two tirzepatide drugs, rival to Novo Nordisk's semaglutide, brought in a combined $8.57bn in the quarter, compared to $4.33bn in Q2 2024. Mounjaro led the growth with approximately $5.2bn, while Zepbound generated around $3.4bn. Mounjaro and Zepbound helped drive the US drugmaker's total Q2 revenue to $15.56bn, up 38% from the same period last year. In a conference call, Eli Lilly CEO David Ricks acknowledged the role the two brands played in the company's revenue, highlighting their strong sales and the company's optimism for high-growth ceilings. Eli Lilly now expects full-year revenue between $60bn and $62bn, up from its previous range of $58bn to $61bn. The raise contrasted with rival Novo Nordisk, which reduced its 2025 outlook last week based on headwinds in the GLP-1RA space. However, shares in Lilly dropped 12% after market open to $656.19 following disappointing data published on the same day for oral weight loss candidate orforglipron. The GLP-1RA arena is set for a major juncture amid the potential approval of more patient-friendly oral versions. Both Novo Nordisk and Eli Lilly are developing candidates in this market and vying for an early lead. Results at orforglipron's highest dose, taken once a day, showed a 12.4% (27.3lb) weight loss at 72 weeks. Novo Nordisk's candidate – which was submitted to the US Food and Drug Administration (FDA) for approval in May 2025 – led to a 13.6% average weight loss. However, Lilly has a strong injectable GLP-1RA foundation on which to build. The 68% growth for Mounjaro, sold in the UK and Europe under the same brand name for both diabetes and weight loss, far surpassed that for Novo Nordisk's Ozempic, which only grew 15% in Q2 compared to the same period last year. Wegovy's global sales fared more favourably, growing 75% in Q2. Wegovy, which has been on the market longer than Zepbound, generated just over $16bn more than Lilly's asset. Analysis by GlobalData still forecasts a higher sales ceiling for tirzepatide by 2031 due to the drug's improved efficacy over semaglutide. Pricing discussions with Trump Eli Lilly is part of a wider pharmaceutical industry battling pricing reforms instigated by US President Donald Trump. The administration is seeking to install a most favoured nation pricing model that would match the costs of certain prescription drugs in the country to the lower prices offered in other developed nations. Executives were coy when asked about potential discussions with Trump, with CEO Ricks saying that 'long term it makes sense to rebalance [pricing].' 'We support the administration's position that medical research costs need to be shared more equitably across developed countries,' Ricks commented. Ricks went on to explain that defects in the US pharma market shift costs to patients and increase red tape. In Pfizer's Q2 earnings call, CEO Albert Bourla said it is in 'very active discussions' around drug pricing. He also confirmed that he personally discussed the matter with Trump, following letters to 17 drugmakers – including Eli Lilly – last week calling for price cuts. "Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Oliver Glasner issues clear Liverpool transfer verdict before Wembley clash - 'Clearly'
Oliver Glasner issues clear Liverpool transfer verdict before Wembley clash - 'Clearly'

Yahoo

time24 minutes ago

  • Yahoo

Oliver Glasner issues clear Liverpool transfer verdict before Wembley clash - 'Clearly'

Liverpool is set to start the 2025/26 season with the Community Shield against Crystal Palace, the 2025 FA Cup champions who upset Manchester City 1-0 in the final. Outside of finalizing a move for one last attacker — seemingly Alexander Isak from Newcastle — and some center-back cover, the Reds have likely finished their summer business. Ahead of Sunday's clash — a game where Virgil van Dijk and Alisson Becker will likely return — Palace manager Oliver Glasner said "you can clearly see a club's ambitions in the transfer market. And it seems that Liverpool FC isn't satisfied with just winning the English league; I think they want to win the Champions League." READ MORE: Liverpool handed double boost before Community Shield as Virgil van Dijk spotted READ MORE: Darwin Nunez showed his true colors with trophy remark as Liverpool transfer exit looms Meanwhile, his Eagles have spent more time trying to win an appeal wth UEFA to reclaim their spot in the 2025/26 Europa League taken from them due to joint ownership issues with Olympique Lyon. At the time of writing, Palace is set to the play in the Conference League. Who has Liverpool signed? The Reds took two players from Bayer Leverkusen in midfielder Florian Wirtz (€125.00m, $156 million) and wing-back Jeremie Frimpong (€40 million, $46.5 million). Liverpool secured striker Hugo Ekitike from Eintracht Frankfurt for €95 million ($110 million) and left-back Milos Kerkez from Bournemouth for €46.9 million ($55 million). Even reserve goalkeeper Armin Pesci was drafted from Paskas AFC for €1.8 million ($2 million). 'They've been playing at this level for years, so I have to say I was a bit surprised that they were so active, but of course it also shows their ambitions," Glasner added. "They obviously saw that we needed to add one or two things to the squad, and they made that very clear and explicit early on this summer.' His Palace side has been far more tepid in the market, having only inked fullback Borna Sosa from Ajax (for a bargin fee) and goalkeeper Walter Benetiz from PSV (free transfer). Glasner joined the Eagles in the second half of the 2024 season and boasts an impressive 45.54% win percentage with the club across 61 matches. In addition to leading Palace to their first trophy, the club's 53 points last season were their most ever in a Premier League season. READ MORE: Jurgen Klopp shared Darwin Nunez warning immediately after signing Liverpool striker READ MORE: How Liverpool could line up with Bradley Barcola in four-way attacking dream Glasner has been successful wherever he's gone. He was named both director of sport and manager at LASK while they played in the Austrian second tier and had them second in the first division within a few seasons. He led German powerhouse Wolfsburg to the Champions League in 2021 for the first time in a decade and then won the Europa League with Eintracht Frankfurt a season later. Glasner also weighed in on the 2025/26 title race. 'Four or five clubs have invested heavily again. If I take City, over €300 million in 2025, Liverpool similarly, I think Arsenal not far behind, Chelsea exactly the same, so you can see that they want to win the Premier League, they want to win the Champions League," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store